Since increasing T-cell activity by blocking MDSC function is an attractive approach for cancer immunotherapy, after GPNMB was identified as a T-cell inhibitory receptor that mediates the suppressive function of MDSCs, the potential of anti-GPNMB mAbs as MDSC-targeted cancer therapeutics has been evaluated in several studies80. Here, GPNMB is linked to cancer.